Inhibitors of BRAF dimers using an allosteric site

BRAF kinase, a critical effector of the ERK signaling pathway, is hyperactivated in many cancers. Oncogenic BRAF(V600E) signals as an active monomer in the absence of active RAS, however, in many tumors BRAF dimers mediate ERK signaling. FDA-approved RAF inhibitors poorly inhibit BRAF dimers, which...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Nat Commun
Päätekijät: Cotto-Rios, Xiomaris M., Agianian, Bogos, Gitego, Nadege, Zacharioudakis, Emmanouil, Giricz, Orsi, Wu, Yang, Zou, Yiyu, Verma, Amit, Poulikakos, Poulikos I., Gavathiotis, Evripidis
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7462985/
https://ncbi.nlm.nih.gov/pubmed/32873792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-18123-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia